Carlsmed appointed Jeffrey Bertolini chief operating officer effective September 8, 2026, raising his annual salary to $475,000 and granting 50,000 stock options. Investors also have a defined incentive structure to assess, with his target cash award rising to 60% of base salary as he assumes responsibility for operations.

Key Highlights

  • Bertolini’s target annual cash incentive increased to 60% of base salary.
  • Carlsmed granted the incoming chief operating officer 50,000 stock options.
  • His employment terms provide salary continuation and incentive payments under specified termination conditions.

Carlsmed, Inc. (NASDAQ: CARL) appointed Jeffrey Bertolini chief operating officer effective September 8, 2026, increasing his annual salary to $475,000. The Leadership change also raises his target annual cash incentive to 60% of base salary and includes a grant of 50,000 stock options.

New COO Receives Expanded Compensation

Bertolini previously served as Carlsmed’s Senior Vice President of Operational Excellence and held its advanced Manufacturing technologies leadership role before that. His employment agreement originally set an annual base salary of $375,000 and a target incentive equal to 40% of base salary, while his salary had later risen to $440,000. The agreement provides for 12 months of continuing base salary after termination without cause or resignation for good reason outside a specified corporate transaction period, along with eligible incentive payments and COBRA reimbursements, subject to a release of claims. Carlsmed also entered into an indemnification agreement with Bertolini, and the company said no family relationships or other reportable material-interest arrangements applied.

Operations Role Targets Greater Scale

Carlsmed said Bertolini made measurable contributions to operations by deploying advanced technologies across its digital production process. Chief Executive Officer and President Michael Cordonnier said the company expects Bertolini’s leadership to expand capabilities and support faster scaling of its personalized surgery business.